The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer

DNA and Cell Biology
Mary R Doherty, Mark W Jackson

Abstract

Triple-negative breast cancer (TNBC) the deadliest form of this disease currently lacks a targeted therapy and is characterized by increased risk of metastasis and presence of therapeutically resistant cancer stem cells (CSC). Recent evidence has demonstrated that the presence of an interferon (IFN)/signal transducer of activated transcription 1 (STAT1) gene signature correlates with improved therapeutic response and overall survival in TNBC patients. In agreement with these clinical observations, our recent work has demonstrated, in a cell model of TNBC that CSC have intrinsically repressed IFN signaling. Administration of IFN-β represses CSC properties, inducing a less aggressive non-CSC state. Moreover, an elevated IFN-β gene signature correlated with repressed CSC-related genes and an increased presence of tumor-infiltrating lymphocytes in TNBC specimens. We therefore propose that IFN-β be considered as a potential therapeutic option in the treatment of TNBC, to repress the CSC properties responsible for therapy failure. Future studies aim to improve methods to target delivery of IFN-β to tumors, to maximize therapeutic efficacy while minimizing systemic side effects.

References

Nov 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ralph R WeichselbaumAndy J Minn
Feb 13, 2009·Nature·Marieke A G EssersAndreas Trumpp
Jan 7, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Xiaoyang LingMichael Andreeff
Mar 14, 2013·Oncoimmunology·Clare Y SlaneyBelinda S Parker
Jan 9, 2014·Nature Communications·Geneviève GarcinGilles Uzé
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Mar 3, 2015·Trends in Immunology·Rebecca A Porritt, Paul J Hertzog
Feb 26, 2016·Nature Reviews. Cancer·Belinda S ParkerPaul J Hertzog
Apr 16, 2016·Drug Discovery Today·Sophie SteelandClaude Libert
Jan 14, 2017·International Journal of Environmental Research and Public Health·Lin-Yu YuXiao-Ping Chen
Aug 30, 2017·Cancer Immunology Research·Natasha K BrockwellBelinda S Parker
Nov 23, 2017·Frontiers in Immunology·Yaozhong HuSerge Muyldermans
Dec 13, 2017·Proceedings of the National Academy of Sciences of the United States of America·Mary R DohertyMark W Jackson

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Mary R DohertyMark W Jackson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nadine M Tung, Eric P Winer
© 2022 Meta ULC. All rights reserved